Routine exercise done at a patient’s own pace improves strength and lessens disability in patients with Charcot-Marie-Tooth (CMT) disease, reports a Canadian study that compared patients adhering to a “self-directed” exercise program with those who do not exercise. The study, “Effects of Self-Selected Exercise on Strength in Charcot–Marie–Tooth Disease…
Flex Pharma announced that its upcoming Phase 2 COMMIT trial investigating the effects of FLX-787 in patients with cramps associated with Charcot-Marie-Tooth (CMT) disease is approved by the Inherited Neuropathies Consortium (INC). The INC is composed of academic medical centers, organizations for patient support and research resources focused…
Five European countries have agreed to Verona Pharma’s plan to begin enrolling patients in a Phase 2b clinical trial of RPL554 as a maintenance treatment for chronic obstructive pulmonary disease, or COPD. The trial will be conducted in the United Kingdom, Germany, Romania, Bulgaria, and the Czech Republic. Verona expects to start…
The United Kingdom’s National Institute for Health and Care Excellence (NICE) recently approved Daxas (roflumilast), developed by AstraZeneca, as a treatment for chronic obstructive pulmonary disease (COPD). The new indication could potentially benefit about 122,000 adults in the U.K. who are estimated to be eligible to receive Daxas, according…
The National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health has granted $10 million to the McDonnell Genome Institute at Washington University to investigate and identify genes associated with chronic obstructive pulmonary disease (COPD) and other lung disorders in people from diverse ethnic backgrounds. Results of…
Get regular updates to your inbox.